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Background. Transcatheter aortic valve implantation (TAVI) is widely used in high risk patients (pts) with aortic stenosis.
Underlying chronic kidney disease implicates a high risk of postprocedural acute kidney injury (AKI). We analyzed its occurrence,
impact on hospital stay, and mortality. Methods. 150 consecutive pts underwent TAVI in our institution (mean age 81± 7 years;
logistic EuroSCORE 24± 15%). AKI definition was a creatinine rise of 26.5 µmol/L or more within 48 hours postprocedural. Ten
patients on chronic hemodialysis were excluded. Results. AKI occurred in 28 pts (20%). Baseline creatinine was higher in AKI pts
(126.4± 59.2 µmol/L versus 108.7± 45.1 µmol/L, P = 0.09). Contrast media use was distributed evenly. Both, 30-day mortality
(29% versus 7%, P < 0.0001) and long-term mortality (43% versus 18%, P < 0.0001) were higher; hospital stay was longer
in AKI pts (20± 12 versus 15± 10 days, P = 0.03). Predicted renal failure calculated STS Score was similar (8.0± 5.0% [AKI]
versus 7.1± 4.0% [non-AKI], P = 0.32) and estimated lower renal failure rates than observed. Conclusion. AKI remains a frequent
complication with increased mortality in TAVI pts. Careful identification of risk factors and development of more suitable risk
scores are essential.
1. Introduction
Calcific aortic valve stenosis has become the most common
acquired valve disorder with the highest prevalence in the
8th or 9th decade of life [1]. Comorbidities such as diabetes
mellitus, stroke, coronary heart disease, peripheral artery
disease, pulmonary disease, and renal impairment appear to
markedly increase the risk of conventional valve replacement
in the elderly and may limit the benefit of surgery in these
patients [2]. Nevertheless, the outcome of untreated aortic
stenosis is dismal once congestive heart failure, angina pec-
toris, or syncope occur. Therefore alternative, less invasive
treatment options are needed. Since the first-in-man tran-
scatheter aortic valve implantation (TAVI) by Cribier et al.
in 2002 [3], more than 50000 procedures were performed
worldwide and this intervention has become an accepted—
assumingly less invasive—treatment alternative for high risk
surgical patients. However, due the comorbidities in these
patients, even TAVI is associated with a number of complica-
tions thatmay lead to impaired outcome. Their closer evalua-
tion and the definition of risk factors as well as measures to
reduce their occurrence are essential and require further
research.
Acute kidney injury (AKI) is a well-known complication
of angiography with the use of iodinated contrast media that
accounts for a significantly prolonged hospital stay and worse
in-hospital outcome [4]. Furthermore AKI has been shown
to be an independent predictor of mortality [5–8]. The most
important risk factor for AKI in patients undergoing stan-
dard heart catheterization is preexisting chronic kidney
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disease [9, 10]. Other risk factors include volume depletion,
hemodynamic instability, and the use of nephrotoxic drugs.
TAVI requires the administration of contrast media
and preexisting kidney disease is frequent in the currently
treated patient population. However, the incidence of AKI,
predictors of this complication, and its impact on outcome
in patients undergoing TAVI have so far been poorly defined.
Therefore, we sought to assess the incidence of AKI,
search for its predictors, and analyze its impact on 30-day as
well as midterm outcome in a sizeable group of consecutive
patients undergoing TAVI.
2. Materials and Methods
A total of 150 consecutive patients with symptomatic aortic
stenosis who underwent TAVI in our institution because they
were either not suitable for conventional surgical valve
replacement or were considered at high operative risk by a
multidisciplinary team including cardiologists and cardiac
surgeons were included in this study. Ten out of 150 patients
had been enrolled in a chronic dialysis program and were
therefore excluded from analysis concerning AKI. Before
intervention, all patients received left and right heart
catheterization. According to the institution policy, written
informed consent was obtained for treatment from each
patient. Blood samples for hematology and serum chemistry
were drawn one day prior to intervention and daily up to 72
hours after treatment. Patients with a previously impaired
kidney function (estimated glomerular filtration rate, eGFR
<60mL/min/1,73m2) received an intravenous prehydration
protocol consisting of saline 0.9% with 1200mg of n-acetyl-
cysteine both 12 hours before and after the procedure.
The vascular access site was evaluated by color-coded
Doppler sonography and CT-angiography. Valve replace-
ment was performed under general anaesthesia, except in one
case which was done under local anaesthesia. All procedures
were performed in the catheter laboratory using fluoro-
scopic guidance and nonionic isoosmolar contrast media
iopromide (ultravist 370 (TM), Schering AG, Berlin, Ger-
many) and transoesophageal echocardiography. The patients
received either a 23 or 26mm Edwards-Sapien valve proth-
esis. Patients not suitable for transfemoral TAVI because of
poor vascular access underwent transapical TAVI.
2.1. Determination of Renal Function. Renal function at base-
line and after 48 hours was determined from serum creati-
nine determined by the method of Jaﬀe´. Since creatinine is
known to be an insuﬃcient marker of renal function but esti-
mated glomerular filtration rate (eGFR) is considered most
suitable we used the modification of diet in renal disease





= 186× (creatinine,mg/dL)−1,154 × (age, years)−0,203
(× 0, 742 in women).
(1)
2.2. Definition of Acute Kidney Injury. Acute Kidney Injury
is divided into three stages by the Acute Kidney Injury
Network: stage 1 is defined as a rise in serum creatinine
≥26.5µmol/L compared to baseline values or an increase in
serum creatinine ofmore than or equal to 50% or a reduction
in urine output as documented oliguria of less than 0.5mL/
kg per hour [12]. In this study AKI was defined as a
26.5 µmol/L rise in serum creatinine 48 hours after procedure
compared to baseline data drawn 24 hours before interven-
tion.
2.3. Prediction of Renal Failure and Mortality. Logistic
EUROScore was calculated by the web-based system (http://
www.euroscore.org/) [13] in advance and results taken for
clinical decision making. STS Score was evaluated retro-
spectively for further analysis including the predicted risk of
renal failure (http://209.220.160.181/STSWebRiskCalc261/
de.aspx). Renal failure by STS Score is defined as an increase
of serum creatinine >176.8 µmol/L, a 50% or greater increase
in serum creatinine over baseline preoperative value, or new
requirement for dialysis.
2.4. Statistics. Diﬀerences in basic clinical characteristics
between groups were tested by chi-square test for categorical
and the ANOVA F-test for continuous variables. The P values
for all of these tests are shown in the tables. Uni- and multi-
variate predictors of AKI were assessed by logistic regression
analysis and odds-ratios (OR) are reported.
Univariate predictors of mortality during followup were
analyzed by Cox regression and calculation of hazard rate
ratios (HR) with 95% confidence intervals (95% CI). Multi-
variate analysis ofmortality was performed by Cox regression
analyses with potential covariates (adjusted HR). As covari-
ates for adjustment, those parameters were chosen which
were found to have a P value lower than 0.05 in univariate
analyses of death.
For all tests, P values <0.05 were considered as signi-
ficant. All statistical analyses were performed with PASW
18.0.0 for Windows.
3. Results
3.1. Baseline Data and Periprocedural Characteristics with
Respect to Diﬀerent Access Mode. The mean age in the patient
group was 81 ± 7 years. In total, 96 patients received valve
replacement via transfemoral (TF) and 54 patients via trans-
apical (TA) approach. 91 (61%) of the patients were female.
Patients with transapical approach were more frequently
male and had significantly more underlying comorbidities
such as hypertension, PAD, CHD, previous CABG, previous
stroke, and impaired kidney function based on baseline
serum creatinine measurement (see Table 1).
Ten patients (7%) had already been enrolled in a chronic
dialysis program before intervention (5% of TF versus and
9% of TA patients, P = 0.006) and were therefore excluded
from analysis concerning AKI.
The average amount of contrast media used in all patients
was 147 ± 58mL. Patients with transfemoral approach
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Table 1: Baseline data and periprocedural characteristics with respect to diﬀerent access modes for valve replacement.
Total Transfemoral Transapical
P
n = 150 n = 96 n = 54
Women, n (%) 91 (61) 66 (69) 25 (46) 0.006
Age, mean ± s.d., years 81 ± 7 82 ± 6 80 ± 7 0.2
Hypertension, n (%) 115 (77) 69 (72) 46 (85) <0.0001
Endstage renal failure, n (%) 10 (7) 5 (5) 5 (9) 0.06
Hypercholesterolemia, n (%) 51 (34) 31 (32) 20 (37) 0.27
Diabetes, n (%) 42 (28) 25 (26) 17 (31) 0.56
Peripheral occlusive disease, n (%) 37 (25) 10 (10) 27 (50) <0.0001
Coronary heart disease, total, n (%) 79 (53) 41 (43) 34 (63) <0.05
(1) vessel disease 25 (17) 13 (14) 12 (22)
(2) vessel disease 20 (13) 14 (15) 6 (11)
(3) vessel disease 34 (23) 14 (15) 20 (37)
Previous myocardial infarction, n (%) 36 (24) 22 (23) 14 (26) 0.42
Previous CABG, n (%) 34 (23) 15 (16) 19 (35) <0.0001
Previous stroke, n (%) 14 (9) 7 (7) 7 (13) 0.024
Baseline creatinine, mean ± s.d., µmol/L 133.5 ± 109.6 116.7 ± 73.4 162.7 ± 150.3 0.013
GFR, mean ± s.d., mL/min/1,73m2 53 ± 22 55 ± 21 49 ± 22 0.11
Baseline hemoglobin, mean ± s.d., mmol/L 7.39 ± 1.06 7.39 ± 1.06 7.39 ± 0.99 0.8
Hemoglobin 24 hours after intervention, mean ± s.d., mmol/L 6.27 ± 0.81 6.27 ± 0.74 6.21 ± 0.93 0.53
Amount contrast dye, mean ± s.d., mL 147 ± 58 160 ± 57 125 ± 53 <0.0001
STS Score renal failure, % ±s.d. 7.3 ± 4.2 6.8 ± 3.5 8.3 ± 5.1 0.054
STS Score mortality, % ±s.d. 6.3 ± 3.5 5.7 ± 2.7 7.1 ± 4.5 0.024
EUROScore, % ±s.d. 24 ± 14 22 ± 13 28 ± 16 0.02
All values are expressed as mean ± s.d. or n (%).
received with 160 ± 57mL of contrast media a significantly
greater amount than patients with transapical access who
received 125± 53mL (P < 0.0001).
3.2. Acute Kidney Injury after Diagnostic Coronary Angiog-
raphy. The rate of AKI after pre-TAVI diagnostic right and
left heart catheterization in our patient population was 9.2%
(n = 13). Only 4 patients (2.8%) developed AKI after
both diagnostic coronary angiography and TAVI procedure
(median 15 days between diagnostic catheterization and
valve procedure).
3.3. Acute Kidney Injury after TAVI. After exclusion of the ten
patients who had already been enrolled in a chronic dialysis
program before TAVI, 140 patients were left for the analysis
concerning the occurrence of acute kidney injury.
The number of patients developing acute kidney injury
was 28 (20%).
Need for transient dialysis occurred in six out of these
28 pts. with AKI (21%). Two patients without AKI needed
short-term dialysis (one patient was hemofiltrated due to low
cardiac output and consecutive renal impairment, another
patient acquired septic shock with renal failure).
There was no significant diﬀerence regarding weight,
height, baseline creatinine, and hemoglobin values in pts.
who developed AKI after intervention compared to those
who did not (see Table 2). Patients with AKI were signifi-
cantly younger (79 ± 9 yrs versus 82 ± 6 yrs, P = 0.008)
and had more frequently comorbidities such as hypertension
and previous CABGwhereas diﬀerences in peripheral arterial
disease, cerebrovascular disease, CHD, and hypercholes-
terolemia did not reach statistical significance.
Although baseline creatinine was slightly higher in the
AKI group (126.4± 59.2µmol/L versus 108.7± 45.1µmol/L,
resp.) this diﬀerence did not also reach statistical significance
which could have been due to the sample size.
The amount of contrast media used during the procedure
was also very similar between groups (147 ± 71mL versus
148± 56mL, P = 0.93).
3.4. Impact of AKI on Hospital Stay and Survival. Mean
hospital stay was significantly longer in pts. with AKI than in
those without AKI (20 ± 12 days versus 15 ± 10 days, P =
0.03).
Both, 30-day-mortality (29% versus 7%, P < 0.0001) and
cumulative mortality after a median followup of 309 days
were significantly higher in AKI patients (43% versus 18%,
P < 0.0001).
Crude and adjusted cumulative survival are shown in
Figure 1. AKI was associated with significantly worse survival
(HRR 2.7, CI 1.34–5.41, P = 0.006, Figure 1(a)). Mortality in
AKI pts. was even higher (HRR 3.8, CI 1.37–10.37, P = 0.01,
Figure 1(b)) after adjusting for risk factors (age, diabetes,
PAD, hypertension, previous myocardial infarction and
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Table 2: Parameters associated with acute kidney injury (AKI).
All (n = 140∗) With AKI (n = 28) Without AKI (n = 112) P value
Age (years) ± s.d. 82 ± 7 79 ± 9 82 ± 6 0.008
Weight (kg) ± s.d. 74 ± 16 76 ±17 74 ± 16 0.535
Height (cm) ± s.d. 167 ± 9 169 ± 9 167 ± 8 0.136
Baseline creatinine (µmol/L) ± s.d. 114.9 ± 53 126.4 ± 59.2 108.7 ± 45.1 0.093
GFR (mL/min/1,73m2) ± s.d. 55 ± 20 51 ± 17 57 ± 20 0.16
Baseline hemoglobin (mmol/L) ± s.d. 7.45 ± 1.06 7.26 ± 1.24 7.45 ± 0.99 0.35
Hemoglobin 24 hours after intervention, mean ± s.d., mmol/L 6.27 ± 0.81 6.21 ± 1.06 6.33 ± 0.74 0.56
Amount of contrast media (mL) ± s.d. 148 ± 59 147 ± 71 148 ± 56 0.93
Diabetes, n (%) 38 (27) 10 (36) 28 (25) 0.19
Hypertension, n (%) 108 (77) 24 (86) 84 (75) 0.007
PAD, n (%) 34 (24) 7 (25) 27 (24) 0.45
Previous stroke, n (%) 11 (8) 2 (7) 9 (8) 0.75
Previous CABG, n (%) 32 (23) 9 (32) 23 (21) 0.02
Previous MI, n (%) 34 (24) 9 (32) 25 (22) 0.06
CHD, n (%) 74 (53) 20 (71) 54 (48) 0.6
Hypercholesterolemia, n (%) 48 (34) 10 (36) 38 (34) 0.73
STS Score renal failure, % ±s.d. 7.3 ± 4.2 8.0 ± 5.0 7.1 ± 4.0 0.32
STS Score mortality, % ±s.d. 6.0 ± 3.4 6.0 ± 3.5 6.0 ± 3.4 0.97
EUROScore, % ±s.d. 24 ± 15 27 ± 19 23 ± 13 0.18
All values expressed as mean ± s.d. or n (%); ∗10 pts. on chronic dialysis excluded.
CABG, left ventricular dysfunction, amount of contrast dye,
baseline creatinine, and hemoglobin).
3.5. Univariate and Multivariate Predictors of AKI. Predictors
of AKI occurrence in univariate and multivariate regression
analysis are shown in Tables 3 and 4. Of all included variables
(age, diabetes, hypertension, PAD, previous CABG, myocar-
dial infarction, left ventricular function, baseline creatinine,
and hemoglobin and amount of contrast dye) only age was
found to be significantly associated with AKI in univariate
analysis and was detected as an independent predictor of
AKI in multivariate analysis (OR 0.93, CI 0.87–0.99, P =
0.03). Including vascular access site in the model, transapical
approach was also a significant predictor of AKI (OR 1.8, CI
1.85–18.4, P = 0.003).
3.6. EuroSCORE and STS Score. Neither EuroSCORE (27 ±
19% versus 23 ± 13, P = 0.18) nor STS Score (6.0 ± 3.5%
versus 6.0± 3.4%, P = 0.97) predicted the marked diﬀerence
in mortality rates between AKI and non-AKI pts (Figure 2).
When applying the STS Score renal failure definition to
our patient population, 19 pts. (13.6%) developed renal fail-
ure. However, the predicted rate of renal failure by STS Score
was only 7.3% (P = 0.023) for all pts. and therefore almost
half of the observed rate. The predicted risk for renal failure
based on the STS Score did not significantly diﬀer between
the TA and TF treatment groups (6.8 ± 3.5% versus 8.3 ±
5.1%, P = 0.054). The observed rate of AKI was however
significantly higher in the TA group (31% versus 11%, P =
0.001) and exceeded thereby markedly the predicted rate of
renal failure 1.6-fold in the TF and 3.7-fold in the TA pts. The
Table 3: Univariate predictors of acute kidney injury.
OR CI 95% P
Age 0.92 0.87–0.98 0.012
Diabetes 1.6 0.66–3.83 0.3
Hypertension 2.0 0.64–6.26 0.23
PAD 1.05 0.4–2.74 0.92
CABG 1.8 0.73–4.58 0.2
MI 1.65 0.66–4.09 0.28
Moderately reduced LV function∗ 1.63 0.56–4.7 0.37
Severely reduced LV function# 1.54 0.44–5.32 0.5
Baseline creatinine 1.92 0.96–3.83 0.06
Baseline hemoglobin 0.89 0.69–1.14 0.35
Amount contrast dye 1.0 0.99–1.01 0.93
∗Moderately impaired left ventricular function (EF = 49–35%), #severely
impaired left ventricular function (EF < 35%); CI: Confidence interval for
Exp (B) 95%.
amount of contrast dye in TA pts. was significantly less than
in the TF pts. (125 mL versus 160 mL, P < 0.0001).
4. Discussion
Acute kidney injury after the use of iodinated contrast
media in angiography is known to account for a number
of adverse eﬀects such as prolonged hospital stay [4] and to
be an independent risk factor of mortality [7–10]. Patients
undergoing TAVI procedures currently belong to an elderly
population with numerous comorbidities. Several investi-
gators have shown that AKI is a relatively frequent com-
plication after TAVI and that it is associated with an increased




























Figure 1: Cumulative survival in pts. with (dotted lines) and without AKI (solid lines). (a) Crude cumulative survival (days) (HRR
2.7, CI 1.34–5.41, P < 0.01). (b) Adjusted cumulative survival (days) (HRR 3.8, CI 1.37–10.37, P = 0.01); adjusted for age, diabetes,
PAD, hypertension, previous myocardial infarction and CABG, left ventricular function, amount of contrast dye, baseline creatinine, and
hemoglobin.
Table 4: Multivariate predictors of acute kidney injury.
OR CI 95% P
Age 0.93 0.87–0.99 0.05
Diabetes 1.3 0.48–3.6 0.6
Hypertension 2.0 0.54–7.41 0.3
PAD 0.76 0.25–2.3 0.62
CABG 1.49 0.5–4.4 0.48
MI 1.08 0.34–3.42 0.89
Moderately reduced LV function∗ 1.85 0.58–5.92 0.3
Severely reduced LV function# 1.0 0.23–4.3 0.9
Baseline creatinine 2.0 0.89–4.54 0.1
Baseline hemoglobin 0.86 0.66–1.14 0.3
Amount contrast dye 1.0 0.99–1.01 0.6
Constant 44.38 0.3
∗Moderately impaired left ventricular function (EF = 49–35%), #severely
impaired left ventricular function (EF < 35%); CI: Confidence interval for
Exp (B) 95%.
mortality [14–17]. However it remains unclear which of
the underlying comorbidities contribute most to the adverse
outcome following AKI. Moreover, reliable predictors of
AKI in this patient population still need to be defined. In
particular, the value of risk scores developed for patients who
undergo open heart surgery remains so far unknown.
In the present study, AKI occurred in 20% of the patients
after TAVI with 4% requiring dialysis. This is within the
range reported by other investigators. Nuis et al. [17] found
very similar rates with 19% for AKI and 2% for temporary
dialysis. While Bagur et al. [14] reported a lower rate of AKI























Figure 2: Morbidity and mortality with respect to access site
and development of acute kidney injury (AKI): observed 30-day
mortality and predicted renal failure and mortality by STS Score
for pts. with and without AKI; AKI = acute kidney injury.
[18] and Kong et al. [19] foundmarkedly higher rates of 28%
and 7.4%, and 28.8% and 6%, respectively. One explanation
for this wide variation of AKI rates could be that the average
amount of contrast media used in these studies diﬀered mar-
kedly, too. While it was 148mL in the present study, Bagur
et al. [14] with the lowest rate of AKI reported <100mL. In
contrast, Aregger et al. [18] with the higher rate of AKI used
242mL on average. The amount of contrast media used dur-
ing angiography is indeed considered one major risk factor
for the development of AKI. Nevertheless, in the present
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study no significant diﬀerence in contrast media use could be
found between AKI und non-AKI patients. The observation
that AKI was not related to the amount of contrast used has
also been reported by other groups [15, 16] suggesting that
other factors may be more important for the development
of renal impairment in the population currently undergoing
TAVI.
Prehydration in addition to intravenous n-acetyl-cys-
teine application prior to contrast media exposure is a well-
known measure to reduce AKI rates in patients with renal
impairment [8]. In our study patients with an eGFR <
60mL/min/1,73m2 were treated with 1000mL of saline 0.9%
and 1200mg of n-acetyl-cysteine which may have prevented
more patients from experiencing AKI than without these
protective measures. Nevertheless, this prevention strategy
in general and even more in this specific patient population
is not eﬀective enough to thoroughly avoid occurrence of
AKI. It can however not be excluded that this therapy had
impact on our results. Therefore hydration therapy may have
contributed to the nonsignificant association between base-
line creatinine and acute kidney injury risk.
Comparing AKI rates and patients after diagnostic and
TAVI catheterization no correlation between AKI after diag-
nostic and valve procedure could be seen implying the lack
of a patient-inherent predisposition for AKI occurrence after
exposure to contrast media.
This finding complies with the results of Van Linden et al.
[20] who stated that early contrast media exposure (1–7
days) by cardiac catheter or CT-Scan did not increase the risk
of AKI or RRT.
In this context it should be kept in mind that after cardiac
surgery without any use of contrast media, the rate of AKI
can also reach up to 30% with 1% requiring dialysis treat-
ment [21, 22]. Bagur et al. [14] reported a 25% incidence of
AKI after surgical aortic valve replacement in patients with
preprocedural chronic kidney disease compared to 12% in
patients undergoing TAVI.
The markedly adverse eﬀect of the occurrence of AKI on
the outcome of TAVI underlines the importance of identi-
fying predictors of this complication as well as appropriate
measures for its prevention. In the present study, 30-day
mortality and midterm mortality were as high as 29% and
43% in patients with AKI compared to only 7% and 18% in
those who did not develop this complication. The diﬀerence
in survival was even more pronounced when adjusting for
diﬀerences in baseline characteristics. Similar findings have
been reported by other investigators [14–17, 23]. Despite
these rather consistent findings with regard to incidence of
AKI after TAVI and its adverse impact on outcome, the data
with regard to risk prediction and options for prevention of
AKI remain controversial.
It appears obvious that preprocedural chronic kidney
disease should be a major risk factor for the development
of postprocedural AKI. Sinning et al. [16] indeed showed
impaired renal function with moderately elevated serum cre-
atinine values before intervention and AKI occurrence unre-
lated to the amount of contrast media to be the strongest pre-
dictors of 1-year mortality among TAVI patients. Although
baseline creatinine in the present study was slightly higher in
the AKI group (126.4±59.2µmol/L versus 108.7±45.1µmol/
L, resp.) this diﬀerence did not reach statistical significance.
This may be due to small sample size and thus lack of statis-
tical power. As a matter of fact, preinterventional serum cre-
atinine was found to be a significant predictor of AKI only in
the study by Elhmidi et al. [15] whereas several other studies
could not confirm this observation [14, 15, 17, 19]. Paradox-
ically, younger age turned out to be the only independent
preprocedural risk factor for the development of AKI in the
present study. This observation must be seen with caution.
To qualify for TAVI instead of conventional surgery, younger
patients must assumingly have been markedly sicker than
older patients. It is therefore likely that this observation is due
to confounding factors. Patients with AKI more frequently
had hypertension and previous bypass surgery. Hyperten-
sion was also found to be a predictor of AKI in other
studies [14, 19]. Without consistency, peripheral artery
disease [15, 16], previous myocardial infarction [17], chronic
obstructive pulmonary disease [14], systemic inflammatory
response [16, 17], residual aortic regurgitation [16], and
periprocedural red blood cell transfusion [14, 15, 19] have
been reported to predict AKI after TAVI. In accordance with
Kong et al. [19], transapical TAVI was found to be associated
with a higher risk of AKI in the present study. Although this
could be partially due to the worse baseline characteristics of
these patients, transapical access remained a significant pre-
dictor after consideration of such diﬀerences. Whether the
more invasive nature of this approach, higher bleeding rates
and requirement for blood cell transfusion account for this
diﬀerence remains to be shown. Nuis et al. [17] found the
logistic EuroSCORE to predict AKI. This could not be con-
firmed in the present study. In addition, similar to previous
reports, the observed 30-day mortality was markedly lower
than predicted by the logistic EuroSCORE (11% versus 24%)
whereas the STS score was indeed lower (6%). This is in
agreement with the observation of Piazza et al. [24] who
found lower estimates of operative mortality by the STS
Score stating that this scoring system has suboptimal dis-
criminatory power and calibration for TAVI patients. STS
score as a surgical risk algorithm obviously omits several risk
factors in the TAVI population leading to diﬀerent patient
selection and thus mortality rates. The present study also
demonstrates that STS score for prediction of renal failure
has little value for prediction of renal failure after TAVI.
This underlines once more the importance of developing
appropriate scores for the risk of death as well as of the risk of
renal failure and other complications in patient populations
currently treated with TAVI.
In addition to preexisting factors, hemodynamic insta-
bility with consecutive extreme hypotension caused by rapid
pacing, balloon valvuloplasty, and prosthesis deployment
during TAVI may account for a significantly higher risk of
AKI in patients undergoing TAVI compared to simple angio-
graphy or PCI. Arteriosclerotic microembolism may also
contribute to temporary deterioration of kidney function.
This must be considered when developing measures to
reduce the occurrence of AKI after TAVI.
This study has several limitations. Although the data were
collected prospectively in consecutive patients undergoing
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TAVI, the analysis with regard to incidence and predictors
of AKI was performed retrospectively. Potentially relevant
factors such as red blood cell transfusion, after procedure
thrombocytopenia and hemoglobin drop, procedure time,
hemodynamic complication or the use of angiotensin
converting enzyme inhibitors, and/or angiotensin receptor
blockers could not be evaluated. Although the study com-
prised a sizeable number of TAVI patients, it reflects a single-
center experience only and a much larger population is
required to perform extensive multivariate analyses in order
to better identify risk factors for the development of AKI with
relevant impact on the decision making in clinical practice.
5. Conclusion
Development of AKI is frequent in patients undergoing
TAVI. Its occurrence does not appear to be primarily related
to the amount of contrast dye used. Furthermore, STS Score
does not reliably predict renal failure in this patient popu-
lation. The occurrence of AKI markedly increases hospital
stay as well as 30-day and midterm mortality even after con-
sideration of the baseline risk profile. Thus, improvements
in predicting the risk of AKI after TAVI as well as eﬀective
measures to reduce the rate of this complication would be
essential.
Abbrevations
AKI: Acute kidney injury
AKIN: Acute kidney injury network
CABG: Coronary artery bypass graft
CHD: Coronary heart disease
EUROScore: European system for cardiac operative risk
evaluation
GFR: Glomerular filtration rate
MI: Myocardial infarction
PAD: Peripheral arterial disease
TA: Transapical
TAVI: Transcatheter aortic valve implantation
TF: Transfemoral
STS Score: Society of Thoracic Surgeons Score.
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